Navigation Links
Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy

e ADAS-cog difference reached statistical significance (observed case analysis; p=0.006). Dimebon's benefit over placebo on the other two endpoints (the MMSE and the NPI) at six months was maintained at one year.

Jeffrey Cummings, MD, the Augustus Rose Professor of Neurology at the University of California, Los Angeles, and Director of the UCLA Alzheimer's Disease Center stated: "I consider these efficacy data to be noteworthy because they show an overall treatment benefit that is consistent, robust and larger at twelve months than at six. To my knowledge, this is the first randomized, double-blind, placebo-controlled study in which statistically significant benefit was achieved on endpoints measuring each of the four most clinically relevant aspects of mild-to-moderate Alzheimer's disease after a full year of therapy. Given these data and the fact that Dimebon was well tolerated in this study, I consider Dimebon one of the most promising Alzheimer's disease compounds in development."

"The natural history of untreated Alzheimer's disease includes decline in thinking abilities, social behavior and function," observed Rachelle Doody, MD, PhD, the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, in Houston, and principal investigator of this study. "By contrast, after a full year of therapy Dimebon-treated patients did not decline in any of these areas. These data demonstrate that, as a group, Dimebon-treated patients stabilized for a full year, whereas placebo-treated patients declined at the expected rate."

Dimebon-treated patients experienced significantly fewer serious adverse events than placebo-treated patients (3.4 percent vs. 11.7 percent, respectively; p=0.03) and dropped out of the study at a rate (31.5 percent) consistent with the dropout rate in the placebo group (37.2 percent). The most frequently reported adverse events associated with treatment were dry mouth (18.0 percent
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
3. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
6. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
7. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
8. EPIX Pharmaceuticals Announces Statistically Significant Results in Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
9. Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of Telcyta as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer
10. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
11. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
Post Your Comments:
(Date:7/28/2014)... , July 28, 2014  A prospective ... Sweden has validated the performance ... platforms and has associated volumetrically assessed breast density ... Cancer Epidemiology, Biomarkers & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), ... a tool for widespread breast cancer risk assessment," ...
(Date:7/28/2014)... , July 28, 2014  TNI BioTech, ... biopharmaceutical company focused on the development, marketing and ... has filed definitive proxy materials with the Securities ... Annual Meeting of Shareholders to be held on ... Standard Time. The record date for determining those ...
(Date:7/28/2014)...  ResMed (NYSE: RMD ), an innovator ... sleep-disordered breathing and other chronic respiratory conditions, has won ... against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), ... 210 and 220 masks.  The judgment was entered by ... , is appealable, and applies throughout Germany.  ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
...  Althea Technologies, Inc., a leading provider of development ... the appointment of Dr. Kristin DeFife as Director, ... and Marketing. (Logo:  http://photos.prnewswire.com/prnh/20020925/LAW010LOGO ... will be responsible for leading Althea,s microbial biologics ...
... May 1, 2012  Intrepid Investment Bankers LLC ("Intrepid"), ... announced the sale of Newport Medical Instruments, Inc. ... closed on May 1, 2012.  Intrepid acted as ... with the transaction.  (Logo:  ...
Cached Medicine Technology:Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing 2Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing 3Intrepid Investment Bankers LLC Advises Newport Medical Instruments, Inc. in its Sale to Covidien plc 2
(Date:7/28/2014)... Medicine (BUSM) report variants in a new gene, PLXNA4, ... (AD). The discovery of this novel genetic association may ... specifically. These findings appear in the Annals of ... dementia affecting 5.4 million Americans including 13 percent of ... percent of people age 85 and older. Genetic factors ...
(Date:7/28/2014)... University of Texas Health Science Center at San Antonio, the ... of pills that cures 9 of 10 hepatitis C patients. ... or without ribavirin, cured 93 percent of patients in 12 ... study published today in The Lancet . , ... Lawitz, M.D., clinical professor in the School of Medicine at ...
(Date:7/28/2014)... The Wireline Services Market in Europe report defines and ... forecast of revenue. The Wireline services market in Europe is ... $2.4 billion by 2019, at a CAGR of 11.2%, for ... Wireline Services Market in Europe report, to get an idea ... of the segmentation in the European Wireline Services market, and ...
(Date:7/28/2014)... America Carotenoids & Antioxidants Market report defines and segments the ... forecast of revenue. This market is estimated to grow from ... at a CAGR of 7.1% from 2013 to 2018. , ... Antioxidants Market report to get an idea of the in-depth ... in the market, and is supported by various tables and ...
(Date:7/28/2014)... -- A common inflammatory muscle disorder that causes ... the risk for heart attack and stroke, ... that patients with polymyalgia rheumatica are more likely ... the blood vessels. Doctors should carefully manage the ... to reduce their risk for complications, the study ...
Breaking Medicine News(10 mins):Health News:Researchers identify potential biomarker for AD 2Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2
... Hawaiians Access to Nursing Home, Assisted Living, Home Care and ... StatewideRICHMOND, Va., April 30 The cost of long term ... putting significant financial pressure on those in or near retirement, ... the same time, the current economic downturn has led to ...
... EPS (1) was $0.42 -- Annual Guidance Narrowed to $2.05 to $2.18 Adjusted Diluted EPS(1) - ... Inc. (NYSE: WST ) today announced its results for the first quarter of 2009. ... Three Months Ended, ... March 31, ...
... - Nuvo Research Inc. (TSX: NRI), a Canadian drug development ... that are delivered to and through the skin using its ... and operational results for the quarter ended March 31, 2009., ... Successfully completed all Pennsaid(R) studies necessary to resubmit, ...
... 2009 Performance Outlook -MELVILLE, N.Y., April 30 Gentiva Health ... of comprehensive home health services, today reported the following 2009 ... Net revenues of $288.9 ... $321.6 million, which included net revenues of $77.8 million from ...
... SUNNYVALE, Calif., April 30 Cepheid (Nasdaq: CPHD ) ... investor conferences, and invited investors to participate via webcast., ... York, NY, Wednesday, May 13, 2009 at 10.40 ... Boston, MA, Tuesday, May 19, 2009 at 8.50 ...
... ... ------- ... $4,150 $4,863 (15%), (Loss) / Income ... ($5.40) $0.56, Special Items ...
Cached Medicine News:Health News:Growth in Hawaii Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Hawaii Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Hawaii Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:West Announces First Quarter 2009 Results 2Health News:West Announces First Quarter 2009 Results 3Health News:West Announces First Quarter 2009 Results 4Health News:West Announces First Quarter 2009 Results 5Health News:West Announces First Quarter 2009 Results 6Health News:West Announces First Quarter 2009 Results 7Health News:West Announces First Quarter 2009 Results 8Health News:West Announces First Quarter 2009 Results 9Health News:West Announces First Quarter 2009 Results 10Health News:West Announces First Quarter 2009 Results 11Health News:West Announces First Quarter 2009 Results 12Health News:West Announces First Quarter 2009 Results 13Health News:West Announces First Quarter 2009 Results 14Health News:West Announces First Quarter 2009 Results 15Health News:West Announces First Quarter 2009 Results 16Health News:West Announces First Quarter 2009 Results 17Health News:West Announces First Quarter 2009 Results 18Health News:Nuvo announces 2009 first quarter financial results 2Health News:Nuvo announces 2009 first quarter financial results 3Health News:Nuvo announces 2009 first quarter financial results 4Health News:Nuvo announces 2009 first quarter financial results 5Health News:Nuvo announces 2009 first quarter financial results 6Health News:Nuvo announces 2009 first quarter financial results 7Health News:Nuvo announces 2009 first quarter financial results 8Health News:Nuvo announces 2009 first quarter financial results 9Health News:Nuvo announces 2009 first quarter financial results 10Health News:Nuvo announces 2009 first quarter financial results 11Health News:Gentiva Reports First Quarter 2009 Results 2Health News:Gentiva Reports First Quarter 2009 Results 3Health News:Gentiva Reports First Quarter 2009 Results 4Health News:Gentiva Reports First Quarter 2009 Results 5Health News:Gentiva Reports First Quarter 2009 Results 6
Slitlamp-mounted contact tonometer for precision tonometry (corneal thickness independent)...
... from the simplicity and ease of the ... history and reputation for accuracy, reliability and ... between rooms. With no wires to ... Retinomax has full measurement range and advanced ...
... fourth generation septal repair implant. It differs ... a unique self-centering mechanism, fabricated from a ... attached to alternating sides of the umbrella ... mechanism which assists to centrally locate the ...
Introducing the Guidant HEARTSTRING Proximal Seal System. A surgically intuitive system that meets the challenge of clampless hemostasis with a design that is elegant in its simplicity and profound i...
Medicine Products: